Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 4
2004 5
2008 1
2009 1
2010 1
2013 1
2014 3
2015 1
2016 1
2017 1
2019 2
2020 3
2021 1
2022 1
2023 1
2024 3
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
Discontinuation of First-Line Disease-Modifying Therapy in Patients With Stable Multiple Sclerosis: The DOT-MS Randomized Clinical Trial.
Coerver EME, Fung WH, de Beukelaar J, Bouvy WH, Canta LR, Gerlach OHH, Hoitsma E, Hoogervorst ELJ, de Jong BA, Kalkers NF, van Kempen ZLE, Lövenich H, van Munster CEP, van Oosten BW, Smolders J, Vennegoor A, Zeinstra EMPE, Barrantes-Cepas M, Kooij G, Schoonheim MM, Lissenberg-Witte BI, Teunissen CE, Moraal B, Barkhof F, Uitdehaag BMJ, Mostert J, Killestein J, Strijbis EMM. Coerver EME, et al. Among authors: hoogervorst elj. JAMA Neurol. 2025 Feb 1;82(2):123-131. doi: 10.1001/jamaneurol.2024.4164. JAMA Neurol. 2025. PMID: 39652340 Free PMC article. Clinical Trial.
Influence of personalized extended interval dosing on the natalizumab wearing-off effect - a sub-study of the NEXT-MS trial.
Toorop AA, Wessels MHJ, Gelissen LMY, Hoitsma E, Zeinstra EMPE, van Rooij LC, van Munster CEP, Vennegoor A, Mostert JP, Wokke BHA, Kalkers NF, Hoogervorst ELJ, van Eijk JJJ, Roosendaal CM, Kragt JJ, Eurelings M, van Genugten J, Nielsen J, Sinnige LGF, Kloosterziel ME, Arnoldus EPJ, van Dijk GW, Bouvy WH, Strijbis EMM, van Oosten BW, de Jong BA, Lissenberg-Witte BI, Rispens T, Uitdehaag BMJ, Killestein J, van Kempen ZLE. Toorop AA, et al. Among authors: hoogervorst elj. J Neurol Sci. 2024 Jul 15;462:123102. doi: 10.1016/j.jns.2024.123102. Epub 2024 Jun 22. J Neurol Sci. 2024. PMID: 38925067 Free article. Clinical Trial.
Low natalizumab trough concentrations are associated with reduced seroconversion of the John Cunningham virus in natalizumab-treated patients with multiple sclerosis.
Gelissen LMY, Toorop AA, Schipper PM, Hoitsma E, Zeinstra EMPE, van Rooij LC, van Munster CEP, Vennegoor A, Mostert J, Wokke B, Kalkers NF, Hoogervorst ELJ, van Eijk J, Roosendaal CM, Kragt JJ, Eurelings M, van Genugten J, Nielsen J, Sinnige LGF, Kloosterziel ME, Arnoldus EPJ, Bouvy WH, Strijbis EM, Oosten BV, De Jong BA, Uitdehaag BMJ, Lissenberg-Witte BI, Loeff FC, Rispens T, Killestein J, van Kempen ZLE. Gelissen LMY, et al. Among authors: hoogervorst elj. J Neurol Neurosurg Psychiatry. 2025 Mar 25:jnnp-2024-335761. doi: 10.1136/jnnp-2024-335761. Online ahead of print. J Neurol Neurosurg Psychiatry. 2025. PMID: 40132877 Free article.
Reliability of serum neurofilament light and glial fibrillary acidic protein for detecting disease activity upon discontinuation of first-line disease-modifying therapy in stable multiple sclerosis (DOT-MS).
Fung WH, Wessels MHJ, Coerver EME, de Beukelaar J, Bouvy WH, Canta LR, Gerlach OHH, Hoitsma E, Hoogervorst ELJ, de Jong BA, Kalkers NF, van Kempen ZLE, Lövenich H, van Munster CEP, van Oosten BW, Smolders J, Vennegoor A, Zeinstra EMPE, Barrantes-Cepas M, Kooij G, Schoonheim MM, Lissenberg-Witte BI, Moraal B, Barkhof F, Uitdehaag BMJ, Mostert J, Teunissen CE, Killestein J, Strijbis EMM. Fung WH, et al. Among authors: hoogervorst elj. J Neurol. 2025 Jul 23;272(8):530. doi: 10.1007/s00415-025-13231-9. J Neurol. 2025. PMID: 40699373 Free PMC article. Clinical Trial.
Whole Exome Sequencing in Multi-Incident Families Identifies Novel Candidate Genes for Multiple Sclerosis.
Horjus J, van Mourik-Banda T, Heerings MAP, Hakobjan M, De Witte W, Heersema DJ, Jansen AJ, Strijbis EMM, de Jong BA, Slettenaar AEJ, Zeinstra EMPE, Hoogervorst ELJ, Franke B, Kruijer W, Jongen PJ, Visser LJ, Poelmans G. Horjus J, et al. Among authors: hoogervorst elj. Int J Mol Sci. 2022 Sep 28;23(19):11461. doi: 10.3390/ijms231911461. Int J Mol Sci. 2022. PMID: 36232761 Free PMC article.
Personalized extended interval dosing of natalizumab in MS: A prospective multicenter trial.
van Kempen ZLE, Hoogervorst ELJ, Wattjes MP, Kalkers NF, Mostert JP, Lissenberg-Witte BI, de Vries A, Ten Brinke A, van Oosten BW, Barkhof F, Teunissen CE, Uitdehaag BMJ, Rispens T, Killestein J. van Kempen ZLE, et al. Among authors: hoogervorst elj. Neurology. 2020 Aug 11;95(6):e745-e754. doi: 10.1212/WNL.0000000000009995. Epub 2020 Jul 20. Neurology. 2020. PMID: 32690785 Clinical Trial.
34 results